Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
Xspray is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment.
Vinge’s team consisted of Dain Hård Nevonen, Louise Nässén, Amanda Sandström and Nora Karlsson (Capital Markets and Public M&A).
